Skip to main content
Triangle logo TriangleGet started

Azacitidine (NCT05554393)

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial): a one-minute explainerNCT055543931 min

Azacitidine trial for Acute Myeloid Leukemia (NCT05554393). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults aged 18–59 with newly diagnosed, untreated, intermediate-risk acute myeloid leukemia, assigned through myeloMATCH after genetic testing. Secondary leukemia and several genetic subtypes, including NPM1-mutated and FLT3-ITD disease, are excluded.

The idea: compare cytarabine and daunorubicin alone, those drugs plus venetoclax, or azacitidine plus venetoclax. Venetoclax blocks BCL-2, a protein that supports leukemia-cell survival. Researchers measure remission without detectable residual disease and compare side effects.

This phase 2 study plans 153 patients. Mary Savoie leads through the Canadian Cancer Trials Group; 166 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.